Leqvio, HCP administered. Why?

[anonymous]

I would love for some knowledgeable people to comment on why in the hell the powers that be chose the HCP administered route. I can’t let this go, perhaps I’m missing something and that’s OK, but I’m posting here to try to get an understanding of why. I often close my eyes and imagine a world where this medication is available at a patient’s local pharmacy after a doctor sits down and clicks on a screen.

 

[anonymous]

I would love for some knowledgeable people to comment on why in the hell the powers that be chose the HCP administered route. I can’t let this go, perhaps I’m missing something and that’s OK, but I’m posting here to try to get an understanding of why. I often close my eyes and imagine a world where this medication is available at a patient’s local pharmacy after a doctor sits down and clicks on a screen.

If you don’t know, that’s the reason you aren’t successful selling it.
Medicare. Medicare is fee for service and pays nicely on Part B, ensuring patients will get approved, can afford it, and HCPs will get paid to administer it. This isn’t hard. Amazes me when I hear a Novartian complain “it’s hard to get.” Umm, it’s your job to sell it to offices (buy) so they can administer it (bill). If your providers “can’t get” it, that’s because you haven’t sold the people in their system who need to be sold on a buy and bill product.
Novartis doesn’t understand supporting a buy and bill sales force either. Pay them (individually) on 867 data and pay them well. That’s all you need to do and they will make it a success. Stupid fools and the area goals.
I knocked it out of the park with Leqvio and now I’m looking for a job. They can’t even keep track of who is selling it for them and protect those sales.
Good riddance.

 

[anonymous]

I know someone who makes over 300K a year selling high end European cars in large metro area. People are very miserable selling medical products. Most of car sales is lease renewals with no cold calling. Pharmaceuticals is the worst!!! Then you are fired. Good luck!!!

 

[anonymous]

If you don’t know, that’s the reason you aren’t successful selling it.
Medicare. Medicare is fee for service and pays nicely on Part B, ensuring patients will get approved, can afford it, and HCPs will get paid to administer it. This isn’t hard. Amazes me when I hear a Novartian complain “it’s hard to get.” Umm, it’s your job to sell it to offices (buy) so they can administer it (bill). If your providers “can’t get” it, that’s because you haven’t sold the people in their system who need to be sold on a buy and bill product.
Novartis doesn’t understand supporting a buy and bill sales force either. Pay them (individually) on 867 data and pay them well. That’s all you need to do and they will make it a success. Stupid fools and the area goals.
I knocked it out of the park with Leqvio and now I’m looking for a job. They can’t even keep track of who is selling it for them and protect those sales.
Good riddance.

Crazy talk. Most offices want no part of buying and billing this medication, I don’t think Leqvio will gain critical mass my friends. Oral PCSK9 coming on quick.

 

[anonymous]

Crazy talk. Most offices want no part of buying and billing this medication, I don’t think Leqvio will gain critical mass my friends. Oral PCSK9 coming on quick.

Cardiology offices don’t, because they don’t have other BnB products. PCP does a lot of BnB already and they manage a lot of LDL too. Look at your data and go where the business is. Of course, you’ll still going to share your bonus with everyone who just caters food for their local cardiology office once a week and then Novartis will cut you in the next reorg.
There are lots of successful BnB products being used every day, Novartis just doesn’t know how to sell them.

 

[anonymous]

I would love for some knowledgeable people to comment on why in the hell the powers that be chose the HCP administered route. I can’t let this go, perhaps I’m missing something and that’s OK, but I’m posting here to try to get an understanding of why. I often close my eyes and imagine a world where this medication is available at a patient’s local pharmacy after a doctor sits down and clicks on a screen.

Pharma companies like to use the frequency of (or lack of ) Injections to claim patients may forget to take/get their meds. Then HCP administered being the solution, puts it under part B/medical benefit, where it seems there's less pressure to negotiate on price.
At least that is what I have gathered.

 

[anonymous]

Cardiology offices don’t, because they don’t have other BnB products. PCP does a lot of BnB already and they manage a lot of LDL too. Look at your data and go where the business is. Of course, you’ll still going to share your bonus with everyone who just caters food for their local cardiology office once a week and then Novartis will cut you in the next reorg.
There are lots of successful BnB products being used every day, Novartis just doesn’t know how to sell them.

Totally agree. Novartis failed in launching this drug correctly. And, Physician Administered drugs are the BEST option for patients and physicians who choose to BNB. The simple reason, Non-Medicare Commercial Patients have access to Leqvio through Specialty Pharmacy or BNB with use of the Copay Card to offset the 20% OOP to patients. The advantage with Leqvio is with the Medicare plus Supplemental patients where it’s basically for free! Although not largely profitable, the BNB physician can usually count on billing Medicare for the Office Visit, and Administration Fee for Leqvio. Additionally, many BNB Physicians take advantage of earning valuable Travel Points or Rebates from their credit card they use to purchase Leqvio from their wholesaler. It‘s the Medicare Advantage patients where neither Leqvio or PCSK9 has an advantage, largely due to the 20% OOP cost to the patient(hopefully Foundation Assistance is available). Again, Novartis failed you.